T1	Participants 62 138	patients with standard-risk disease following haploidentical transplantation
T2	Participants 276 430	patients receiving hematopoietic SCT without ex vivo T-cell-depletion from haploidentical donors, 224 patients with standard-risk hematological malignancy
